ADC

Mabion and KriSan Sign Agreement for BIO Asia-Taiwan. Expanding Opportunities for Next-Generation ADC Services.

Mabion and KriSan Biotech sign Agreement to strengthen next-generation ADC services

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

NMPA approves first bispecific antibody-drug conjugate: a new treatment for nasopharyngeal carcinoma

Analytical Development Project for WPD401

Mabion Completes Analytical Development Project for WPD401

Mabion Awards €500,000 CDMO Services to WPD Pharmaceuticals for Breakthrough ADC Project

Mabion Awards €500,000 CDMO Services to WPD Pharmaceuticals for Breakthrough ADC Project

They understood how the immune system is kept in check: The 2025 Nobel prize in physiology or medicine